drugset

drugset / Trial / NCT06396039

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

NCT06396039 ↗

Phase 4 Active not recruiting 84 enrolled Bristol-Myers Squibb

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the effectiveness and safety of ozanimod in Chinese adults with relapsing multiple sclerosis.

Timeline

Start: 2024-05-15
Primary completion: 2028-12-29
Completion: 2029-03-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ozanimod	Small molecule	—	Oral

Indications